Novel Insights into Diagnosis and Therapy of Advanced Renal Cell Carcinoma

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 743

Special Issue Editor


E-Mail Website
Guest Editor Assistant
Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation—Urology, University of Bari “Aldo Moro”, 70124 Bari, Italy
Interests: kidney cancer; prostate cancer; kidney transplantation; metabolomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Renal cell carcinoma (RCC) is the most common type of kidney cancer, and in recent years, there has been a growing interest in identifying tumor markers not only for diagnostic purposes but also to improve the predictive power of clinical and pathological parameters. The progressive introduction of high-throughput technologies has led to a greater understanding of molecular mechanisms underlying the development of RCC and the identification of novel potential therapeutic targets.

The treatment landscape for advanced or metastatic RCC is rapidly evolving, with risk stratification being a crucial step in developing a treatment plan. Cytoreductive nephrectomy (CN) and surgical metastasectomy are still considered fundamental treatments in selected cases after evaluation by a multidisciplinary team. However, recent studies have shown that CN may not always be necessary, especially with the availability of systemic therapies like immune checkpoint inhibitor-based combinations that have shown superior outcomes compared to monotherapy with tyrosine kinase inhibitors.

This Special Issue of Biomedicines is dedicated to studies exploring the application of different approaches to understand the alterations in biological systems occurring in the pathogenesis of advanced RCC, as well as minimally invasive treatment and translational research for the diagnosis and management of this tumor.

Prof. Dr. Giuseppe Lucarelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • renal cell carcinoma
  • kidney cancer
  • therapeutic targets

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 10695 KiB  
Article
Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal Cell Carcinoma: Possible Role of MET and Hepatocyte Growth Factor Activation-Targeted Combined Therapy
by Takahiro Akioka, Shoichi Kimura, Yuichi Katayama, Masato Fujii, Takumi Kiwaki, Makiko Kawaguchi, Tsuyoshi Fukushima, Yuichiro Sato, Shoichiro Mukai, Toshiyuki Kamoto and Atsuro Sawada
Biomedicines 2025, 13(4), 811; https://doi.org/10.3390/biomedicines13040811 - 28 Mar 2025
Viewed by 439
Abstract
Background: Increased expression of MET and hepatocyte growth factor (HGF)-related molecules has been positively correlated with poor prognosis in renal cell carcinoma (RCC). In the current study, the expression and phosphorylation of MET in metastatic RCC (mRCC) are determined by immunohistochemistry, and the [...] Read more.
Background: Increased expression of MET and hepatocyte growth factor (HGF)-related molecules has been positively correlated with poor prognosis in renal cell carcinoma (RCC). In the current study, the expression and phosphorylation of MET in metastatic RCC (mRCC) are determined by immunohistochemistry, and the therapeutic effect of MET and HGF activation-targeting agents for RCC cell lines is analyzed. Methods: Immunohistochemistry was performed for 76 formalin-fixed paraffin-embedded specimens (primary tumor: 32, metastatic site: 44). The therapeutic effect of capmatinib (MET-I) and SRI-31215 (inhibitor of HGF-activating proteases: HGFA-I) was determined based on the inhibition of MET phosphorylation, cell proliferation, and cell migration in 786-O and caki-1 cell lines. Results: Increased expression and phosphorylation of MET were observed in both primary tumor and metastatic sites; however, phosphorylation was significantly upregulated in metastatic sites (p = 0.0001). In an assay of RCC cell lines, the strongest inhibition of MET phosphorylation, cell proliferation, and migration was confirmed with the combined used of MET-I and HGFA-I. Conclusions: Phosphorylation of MET was significantly upregulated in metastasis, which suggested the importance of downregulation in the treatment of mRCC. Our findings suggest that dual inhibition of MET and HGF activation may offer a promising strategy for mRCC treatment, warranting further clinical validation. Full article
Show Figures

Figure 1

Back to TopTop